Flora Mulkey

2.3k citations
34 papers · 1.4k · h-index 17

Impact in

Papers in

  • Oncology 15
    • Cancer Immunotherapy and Biomarkers 6
    • Colorectal Cancer Treatments and Studies 4
  • Hematology 13
    • Acute Myeloid Leukemia Research 7
    • Chronic Myeloid Leukemia Treatments 5
    • Multiple Myeloma Research and Treatments 5
Co-authors
Rajeshwari Sridhara (9 shared papers)Richard Ohrbach (4 shared papers)Joel D. Greenspan (4 shared papers)Roger B. Fillingim (4 shared papers)William Maixner (4 shared papers)Gary D. Slade (3 shared papers)Sirisha L. Mushti (4 shared papers)Charles Knott (3 shared papers)
Journals
Journal of Clinical Oncology (6 papers)Journal of Pain (4 papers)Blood (4 papers)Cancer (2 papers)Clinical Cancer Research (2 papers)
Partner nations
United StatesJapanCanada

In The Last Decade

Flora Mulkey

31 papers receiving 1.4k citations

Peers

Flora Mulkey
Comparison fields: 5 of 96
  • Complementary and Manual Therapy 411
  • Hematology 309
  • Oncology 439
  • Neurology 236
  • Physiology 359
Replace Joon‐Kee Yoon with:
Joon‐Kee Yoon South Korea
Tetsu Yamamoto Japan
István Takács Hungary
Mikaël Cohen France
Maria Chiara Gerardi Italy
Susanne Koeppen Germany
Paola Rizzo Italy
Kai-Hua Chen China
Uzma Haque United States
Diletta Angeletti Italy
Flora Mulkey relative to Joon‐Kee Yoon South Korea Joon‐Kee Yoon's profile →
Citations per field
00.5×10×20×28.1×
Joon‐Kee Yoon · 1×
Citations per year

Countries citing papers authored by Flora Mulkey

Since Specialization
Citations

This map shows the geographic impact of Flora Mulkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flora Mulkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flora Mulkey more than expected).

Fields of papers citing papers by Flora Mulkey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flora Mulkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flora Mulkey. The network helps show where Flora Mulkey may publish in the future.

Co-authors

The 25 scholars most cited alongside Flora Mulkey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Flora Mulkey Line = papers co-authored together Flora Mulkey links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Clinical Findings and Pain Symptoms as Potential Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control Study
Journal of Pain ·Richard Ohrbach, Roger B. Fillingim, Flora Mulkey, Yoly González, Sharon M. Gordon, Henry A. Gremillion, Pei-Feng Lim, Margarete Ribeiro-Dasilva, Joel D. Greenspan, Charles Knott, William Maixner, Gary D. Slade
2011264
2
Pain Sensitivity Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case Control Study
Journal of Pain ·Joel D. Greenspan, Gary D. Slade, Eric Bair, Ronald Dubner, Roger B. Fillingim, Richard Ohrbach, Charlie Knott, Flora Mulkey, Rebecca Rothwell, William Maixner
2011165
3
Study Methods, Recruitment, Sociodemographic Findings, and Demographic Representativeness in the OPPERA Study
Journal of Pain ·Gary D. Slade, Eric Bair, Kunthel By, Flora Mulkey, Cristina Baraian, Rebecca Rothwell, Maria Reynolds, Vanessa Miller, Yoly González, Sharon M. Gordon, Margarete Ribeiro-Dasilva, Pei Feng Lim, Joel D. Greenspan, Ron Dubner, Roger B. Fillingim, Luda Diatchenko, William Maixner, Dawn Dampier, Charles Knott, Richard Ohrbach
2011125
4
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
The Lancet Oncology ·Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha L. Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B. Goldberg, Meredith K. Chuk, Dow-Chung Chi, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M. Blumenthal, Patricia Keegan, Richard Pazdur, Marc R. Theoret
2018112
5
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
Clinical Cancer Research ·Sirisha L. Mushti, Flora Mulkey, Rajeshwari Sridhara
2018108
6
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Journal of Clinical Oncology ·Steven M. Devine, Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, Yi‐Bin Chen, Ravi Vij, James L. Slack, Robert J. Soiffer, Richard A. Larson, Thomas C. Shea, Vera Hárs, Alexander B. Sibley, Sergio Giralt, Shelly Carter, Mary M. Horowitz, Charles Linker, Edwin P. Alyea
2015100
7
Potential Autonomic Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control Study
Journal of Pain ·William Maixner, Joel D. Greenspan, Ronald Dubner, Eric Bair, Flora Mulkey, Vanessa Miller, Charles Knott, Gary D. Slade, Richard Ohrbach, Luda Diatchenko, Roger B. Fillingim
201188
8
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)
Haematologica ·Meir Wetzler, D. Watson, Wendy Stock, Greg Koval, Flora Mulkey, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, C. D. Bloomfield, Claudia Linker, Richard A. Larson
201368
9
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Journal for ImmunoTherapy of Cancer ·Flora Mulkey, Marc R. Theoret, Patricia Keegan, Richard Pazdur, Rajeshwari Sridhara
202059
10
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review
Clinical Cancer Research ·Paz J. Vellanki, Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodríguez, Yibo Wang, Yuan Xu, Hong Zhao, Jiang Liu, Grant A. Howe, Jian Wang, Qiuyi Choo, Sarah J. Golding, Victoria Mansell, Kwadwo Ameyaw Korsah, Dianne Spillman, R. Angelo de Claro, Richard Pazdur, Julia A. Beaver, Harpreet Singh
202141
11
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from fourCALGB(alliance) clinical trials
American Journal of Hematology ·Jorge J. Castillo, Flora Mulkey, Susan Geyer, Jonathan E. Kolitz, William Blum, Bayard L. Powell, Stephen L. George, Richard A. Larson, Richard M. Stone
201539
12
Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
Leukemia & lymphoma ·Rebecca DeBoer, Gregory Koval, Flora Mulkey, Meir Wetzler, Steven M. Devine, Guido Marcucci, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield, Susan Geyer, Charles G. Mullighan, Wendy Stock
201635
13
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
Cancer ·Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William Kevin Kelly, Howard L. McLeod
201427
14
Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy
Clinical Pharmacology & Therapeutics ·Katherina C. Chua, Chenling Xiong, Carol Ho, Taisei Mushiroda, J Chen, Flora Mulkey, Dongbing Lai, Bryan P. Schneider, Sara R. Rashkin, John S. Witte, Paula N. Friedman, Mark J. Ratain, Howard L. McLeod, Hope S. Rugo, Lawrence N. Shulman, Michiaki Kubo, Kouros Owzar, Deanna L. Kroetz
202025
15
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)
American Journal of Hematology ·Peter M. Voorhees, Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera, Flora Mulkey, Misty Bova‐Solem, Katelyn Santo, Destin Carlisle, Philip L. McCarthy, Paul G. Richardson
202117
16
Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)
Blood ·Kelly J. Norsworthy, Flora Mulkey, Ashley F. Ward, Donna Przepiorka, Albert Deisseroth, Ann T. Farrell, Richard Pazdur
201817
17
Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results
Blood ·Peter M. Voorhees, Flora Mulkey, Hani Hassoun, Claudia E. Paba‐Prada, Yvonne A. Efebera, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera J. Suman, Paul G. Richardson
201517
18
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Investigational New Drugs ·Pankaj Gupta, Flora Mulkey, Robert P. Hasserjian, Ben L. Sanford, Ravi Vij, David D. Hurd, Olatoyosi Odenike, Clara D. Bloomfield, Kouros Owzar, Richard M. Stone, Richard A. Larson
201315
19
FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.
Journal of Clinical Oncology ·Aviva C. Krauss, Flora Mulkey, Yuan-Li Shen, Amy S. Rosenberg, Barry W. Miller, Theresa Carioti, K.W. Scott, Nicole Gormley, Marc R. Theoret, Rajeshwari Sridhara, Ann T. Farrell, Richard Pazdur
201815
20
FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.
Journal of Clinical Oncology ·Christy Osgood, Flora Mulkey, Pallavi S. Mishra‐Kalyani, Steven J. Lemery, Ashley V. Ward, Patricia Keegan, Rajeshwari Sridhara, Marc R. Theoret, Richard Pazdur
201914

About Flora Mulkey

Flora Mulkey is a scholar working on Oncology, Hematology, Molecular Biology, Cancer Research and Statistics and Probability, having authored 34 papers that have together received 1.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (7 papers), Statistical Methods in Clinical Trials (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Acute Lymphoblastic Leukemia research (5 papers), Cancer Genomics and Diagnostics (5 papers), Chronic Myeloid Leukemia Treatments (5 papers), Multiple Myeloma Research and Treatments (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Complementary and Manual Therapy (411 citations), Hematology (309 citations), Oncology (439 citations), Neurology (236 citations) and Physiology (359 citations). Flora Mulkey has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Rajeshwari Sridhara, Richard Ohrbach, Joel D. Greenspan, Roger B. Fillingim, William Maixner, Gary D. Slade, Sirisha L. Mushti, Charles Knott, Eric Bair and Richard Pazdur. Their work appears in journals such as Journal of Clinical Oncology, Journal of Pain, Blood, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joon‐Kee YoonBreakdown of academic impact, for papers by Tetsu YamamotoBreakdown of academic impact, for papers by István TakácsBreakdown of academic impact, for papers by Mikaël CohenBreakdown of academic impact, for papers by Maria Chiara GerardiBreakdown of academic impact, for papers by Susanne KoeppenBreakdown of academic impact, for papers by Paola RizzoBreakdown of academic impact, for papers by Kai-Hua ChenBreakdown of academic impact, for papers by Uzma HaqueBreakdown of academic impact, for papers by Diletta Angeletti